Skip to main content

Dr. Mark A. Schroeder, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
23
In the NPI registry since
2007
Medicare patients seen, 2024
372

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2003Medical school: University of Cincinnati College of Medicine
  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    MO license 2006002068

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
372
Services billed
35,079
Patients’ average age
71
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, daratumumab, 10 mg and hyaluronidase-fihj15,48036
Injection, fosaprepitant, 1 mg3,75019
Injection, dexamethasone sodium phosphate, 1 mg1,25054
Injection, bortezomib, 0.1 mg98014
Injection, palonosetron hcl, 25 mcg52032
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes46487
Insertion of needle into vein for collection of blood sample435129
Established patient office or other outpatient visit, 30-39 minutes230104
Injection, granisetron hydrochloride, 100 mcg22013
Injection of additional new drug or substance into vein20166

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 4 payments worth $63,113 in total to this clinician.

By company
GlaxoSmithKline, LLC.$63,113
By type
Consulting Fee$63,113

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Feb 17, 2025GlaxoSmithKline, LLC.
Feb 17, 2025
Consulting Fee$22,688
Aug 28, 2025GlaxoSmithKline, LLC.
Aug 28, 2025
Consulting Fee$22,138
May 12, 2025GlaxoSmithKline, LLC.
May 12, 2025
Consulting Fee$11,275
Nov 13, 2025GlaxoSmithKline, LLC.
Nov 13, 2025
Consulting Fee$7,013

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Missouri →

Industry-funded research

Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $193,221 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexam…
    Janssen Research & Development, LLC
  • A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination WithDaratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexam…
    Janssen Research & Development, LLC
  • A Phase 1b Dose Escalation Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma
    Janssen Research & Development, LLC
  • Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment
    Roche Products Limited

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Saint Louis

Sources

NPI registry (CMS NPPES, November 2026; record last updated April 17, 2025), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1255544680. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.